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Broad-based, host-targeted therapeutics have the potential to ameliorate viral infec-
tions without inducing antiviral resistance. We identified lanthionine synthetase C-like 2 
(LANCL2) as a new therapeutic target for immunoinflammatory diseases. To examine the 
therapeutic efficacy of oral NSC61610 administration on influenza, we infected C57BL/6 
mice with influenza A H1N1pdm virus and evaluated influenza-related mortality, lung 
inflammatory profiles, and pulmonary histopathology. Oral treatment with NSC61610 
ameliorates influenza virus infection by down-modulating pulmonary inflammation 
through the downregulation of TNF-α and MCP-1 and reduction in the infiltration of 
neutrophils. NSC61610 treatment increases IL10-producing CD8+ T cells and macro-
phages in the lungs during the resolution phase of disease. The loss of LANCL2 or neu-
tralization of IL-10 in mice infected with influenza virus abrogates the ability of NSC61610 
to accelerate recovery and induce IL-10-mediated regulatory responses. These studies 
validate that oral treatment with NSC61610 ameliorates morbidity and mortality and 
accelerates recovery during influenza virus infection through a mechanism mediated by 
activation of LANCL2 and subsequent induction of IL-10 responses by CD8+ T cells and 
macrophages in the lungs.
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inTrODUcTiOn
Seasonal influenza causes an estimated 200,000 hospitalizations and 25,000–35,000 deaths annually 
in the United States, afflicting mainly people older than 65 years of age (1). Aside from the seasonal 
flu, pandemic influenza originating from emerging strains can significantly change the disease 
dynamics. Influenza pandemics cause considerable disease, with associated mortality ranging from 
approximately 50 million deaths during the 1918 pandemic to 1 to 4 million deaths in 1957 and 
approximately 1 million deaths in 1968. In 2009, a novel H1N1 virus emerged and spread rapidly 
in humans, causing severe disease in susceptible populations and high numbers of respiratory- and 
cardiovascular-related deaths (2). Overall, seasonal flu is one of the most relevant infectious disease-
related public health problems since it causes important economic losses ranging from 71 to 166 
billion dollars during one influenza pandemic (3).
Current approaches for the prevention and treatment of influenza infections include vaccination 
and early administration of antiviral drugs (4). Typically, a minimum of 6 months are needed to 
develop a new vaccine, creating a lag period between the identification of a new strain and the admin-
istration of the first vaccine doses, in which the population is unprotected against the virus (5). The 
use of antiviral drugs is associated with the emergence of resistance. A promising therapeutic avenue 
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is the modulation of the host response to the virus by targeting 
the immune system in the pulmonary mucosa and systemically 
to minimize viral pneumonia and improve survival rates (6). 
The excessive release of pro-inflammatory cytokines in the lungs 
often leads to a cytokine storm, which is a key contributor to lung 
immunopathology and disease severity. For example, mortality 
induced by the highly pathogenic H5N1 strain correlates with 
high levels of circulating cytokines and chemokines (7). Hence, 
the use of drugs that target the host response instead of directly 
targeting the virus or its cytopathic effects is receiving attention 
for the treatment of infections (8, 9). In contrast to vaccines, 
immune modulators and inflammation blockers provide efficacy 
independently of changes in viral antigenicity, are fast acting, 
and are relatively inexpensive (10), although they have not been 
approved as host-targeted therapeutics. Moreover, in contrast to 
antivirals, immune modulators do not cause resistance.
We have recently investigated the potential role of abscisic acid 
(ABA), as a ligand of lanthionine synthetase C-like 2 (LANCL2) 
leading to elevation of intracellular cAMP and activation of 
protein kinase A (PKA) (11). We used molecular modeling 
approaches to predict the binding of ABA to LANCL2 (12). 
In vitro studies have confirmed direct binding of ABA to LANCL2 
(13). Moreover, oral administration of ABA as a pre- and post-
exposure therapeutic upregulates LANCL2 expression in the 
lungs of influenza-infected mice, reduces influenza virus-related 
immunopathology, and accelerates recovery in infected mice 
(14). LANCL2 is widely expressed in specialized organs of the 
immune system, including blood, spleen, lymph node, and thy-
mus. LANCL2 is expressed by T cells, macrophages, endothelial 
and epithelial cells, and dendritic cells suggesting its potential as a 
target for immunoregulation (15). Other members of the LANCL 
family of proteins include LANCL2 which has been shown to 
contribute to cellular homeostasis and nervous system disorders 
(16, 17).
In this study, we examined the feasibility of using LANCL2 
ligands to induce immunoregulatory responses and ameliorate 
morbidity and mortality associated with influenza virus infec-
tion. PubChem compound 247228, a 3,3′-bis(benzimidazolyl) 
terephthalanilide (BTT), also known as NSC61610 was selected 
from the National Cancer Institute Diversity Set II by LANCL2 
structure-based virtual screening and previously shown to induce 
immunomodulatory effects in mouse models of colitis (18, 19). 
Additionally, the safety and efficacy profiles of BT-11, a newly 
developed LANCL2 ligand, are excellent based on single and 
14-day repeated-dose toxicology studies in rats and in four mouse 
models of inflammatory bowel disease (IBD) (20–23). Given 
the demonstrated efficacy of ABA in accelerating recovery in 
mouse models of influenza virus infection (14), in this study, we 
investigated the effects of NSC61610 in a mouse model of infec-
tion, elucidating its underlying immunoregulatory mechanisms, 
LANCL2 dependency, and cell specificity in the lungs.
MaTerials anD MeThODs
animal Procedures
Eight- to ten-week-old wild-type C57BL/6 mice and LANCL2 
knockout mice on a C57BL/6 background were challenged 
intranasally with 350 pfu/mouse of Influenza A H1N1pdm strain. 
NSC61610-treated mice within this study received 20  mg/kg/
day of NSC61610 orally by gavage. Formulations of NSC61610 
treatment were prepared in PBS containing 25 mg 2-hydroxypro-
pyl-beta-cyclodextrin (HPBCD) per mg NSC61610. Untreated 
mice received equal volume of sterile PBS containing HPBCD. 
NSC61610 was given from day 0 to day 12, daily in 24-hour inter-
vals. Mice treated with oseltamivir phosphate were given 10 mg/
kg/day in two doses separated by 12 h. All mice were weighed 
daily. Mice were housed at the animal facilities at Virginia Tech. 
Mice (n = 10–15 per group and time point) were sacrificed at 3, 
7, or 12 days post-infection (dpi), and samples were collected for 
analysis of gene expression, immunophenotyping of infiltrating 
cells, and histopathological examination. IL-10 neutralization 
was conducted by intraperitoneal injection of anti-IL10 anti-
body (R&D Systems #MAB417); 100  μg/mouse was injected 
on the same day as NSC61610 treatment initiation. The initial 
dosage was followed with a 50-μg/mouse dose on days 6 and 9 
post-infection.
All experimental procedures were approved by the Institutional 
Animal Care and Use Committee (IACUC) of Virginia Tech and 
met or exceeded requirements of the Public Health Service/
National Institutes of Health and the Animal Welfare Act. The 
IACUC approval IDs for the study were 10-157-VBI and 14-007-
VBI. Mice were monitored every 4 h post-infection and humanely 
euthanized.
histopathology
Lung samples were collected at 3, 7, or 12  days post-infection 
and fixed in 10% buffered formalin. Samples were stained with 
hematoxylin and eosin and lesions were graded 0–4 on the fol-
lowing categories: (1) epithelial necrosis, (2) perivascular cuffing, 
(3) leukocytic infiltration of the mucosa and submucosa of large 
airways, and (4) terminal airway infiltration. Tissue slides were 
examined in an Olympus microscope (Olympus America Inc., 
Dulles, VA, USA).
Quantitative real-time rT-Pcr
Total RNA was isolated from lungs. Quantitative PCR was per-
formed on the cDNA using Taq DNA polymerase (Invitrogen, 
Carlsbad, CA, USA) and using previously described conditions 
(24). Purified amplicons were used to optimize quantitative real-
time RT-PCR conditions and to generate standard curves. Primer 
concentrations and annealing temperatures were optimized for 
the iCycler iQ system (Bio-Rad) for each set of primers using 
the system’s gradient protocol. cDNA concentrations for genes of 
interest were examined by RT-PCR using an iCycler IQ System 
and the iQ SYBR green supermix (Bio-Rad) (24). A standard 
curve was generated for each gene using 10-fold dilutions of puri-
fied amplicons starting at 5 pg of cDNA. In order to determine 
the number of products synthesized during the real-time PCR, a 
melting curve analysis was performed on each product. RT-PCR 
was used to measure the starting amount of nucleic acid of each 
unknown sample of cDNA on the same 96-well plate. Results are 
presented as starting quantity of target cDNA (picograms) per 
microgram of total RNA as previously described (24).
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immunophenotyping of immune cells 
infiltrating the lungs of Mice
The whole left lobe was collected in 15  mL of 1× RPMI sup-
plemented with FBS, HEPES, and calcium chloride and chopped 
into small pieces to facilitate the digestion. Lung digestion was 
performed by adding 300 U/mL of Collagenase and 50 U/mL of 
DNAse and incubated for 60–90  min at 37°C under agitation. 
Cell yield was measured in a particle counter (Beckman Coulter) 
after digestion and subsequent filtration through 100 µm strain-
ers. Red blood cells were eliminated by hypotonic lysis, and cells 
were finally resuspended in 1 mL of PBS containing 5% serum 
and 0.09% sodium azide (FACS buffer). Cells were incubated with 
combinations of up to 9 antibodies to markers [CD3 (clone: 145-
2C11), CD4 (clone: GK1.5), CD8 (clone: 53-6.7), CD11b (clone: 
M1/70), CD11c (clone: HL3), CD19 (clone: MB19-1), CD45 
(clone: 30-F11), F4/80 (clone: BM8), Gr1 (clone: 1A8), Ly6C 
(clone: HK1.4), MHC-II (clone: M5/114.15.2), NK1.1 (clone: 
PK136), SiglecF (clone: E50-2440), CX3CR1 (clone: AHP566), 
CD64 (clone: X54-5/7.1), PD-1 (clone: J43), and IL-10 (clone: 
JES5-16E3)]. Antibodies were purchased from eBioscience with 
the exception of CD11b, CD64, and SiglecF (Becton Dickinson) 
and CX3CR1 (BioRad). Thirty thousand events were computed 
in a LSRII flow cytometer (Becton Dickinson). Hematopoietic 
cell phenotype analysis was performed in FACS diva with the fol-
lowing gating discrimination: (1) live cells based of FS versus SS, 
(2) doublet exclusion based on FSC versus FSW, and (3) selection 
of CD45+ events.
Plaque assay
MDCK cells were grown to confluency within six-well plates. 
Cells were washed of serum containing media prior to exposure. 
Serial dilutions of virus sample were made in serum-free growth 
media containing fraction V BSA. Cells were incubated with 
1 mL of virus dilution for 1 h at 37°C. Supernatant was removed 
and cells were washed. Cells were overlayed with a MEM agar 
mixture and incubated for 72 h. Overlay was removed, and wells 
were stained with crystal violet. Lowest dilution with at least 50 
plaques was counted.
expression and Purification of the 
recombinant lancl2 Proteins
Transformed BL21(DE3) E. coli cells were initially cultured 
in Luria-Bertani medium with 100  µg/mL ampicillin at 
37°C 240  RPM until the culture reached an A600 of 0.3. GST-
LANCL2 was expressed by adding 0.1  mM isopropyl-β-d-
thiogalactopyranoside. Induced cells were incubated for 16 h at 
20°C 170 RPM. Cells were harvested by centrifugation 45 min 
1,559 RCF and lysed by sonication in 50 mM Tris–HCl, pH 8.0, 
150  mM NaCl with 0.3  mM Tris(2-carboxyethyl)phosphine 
(TCEP). Post membrane disruption, lysates were centrifuged 
at 17,211 RPM for 20 min at 4°C. GST-LANCL2 fusion protein 
was purified by affinity chromatography using Glutathione 
(GSH)-Sepharose-4B (GE Healthcare). GST-LANCL2 was eluted 
from GSH-Sepharose-4B by incubating the resin with 10  mM 
GSH in 50 mM Tris–HCl, pH 8.0, 150 mM NaCl with 0.3 mM 
TCEP. GST-LANCL2 proteins were run through a gel filtration 
column. The fusion proteins were further purified by the AKTA 
Fast protein liquid chromatography purification systems (GE 
Healthcare). Protein concentrations were determined by bicin-
choninic acid assay. Protein purity was assessed by SDS-PAGE; 
gels were stained with ProSieve Blue Protein Staining solution.
sensor chip Preparation
Direct binding experiments were performed via the Biacore 
T200 surface plasmon resonance (SPR) Technology (Georgetown 
University). The flow rates were 10  µL/min for all capture and 
initial testing studies and 100  µL/min for affinity studies. The 
GST-LANCL2 was immobilized to a CM4 chip by amine cou-
pling method. Two adjacent surfaces were activated by injection 
of a 1:1 (v:v) mixture of 0.1  M N-hydroxysuccinimide (NHS) 
and 0.4  M 1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimide 
hydrochloride (EDC) for 720 s. Experimental flow cell was then 
injected with the GST-LANCL2 that was diluted in 10 mM pH 
5.5 sodium acetate buffer to a final concentration of 25 µg/mL. 
Both experimental and the reference flow cells were inactivated 
by injection of 1 M Ethanolamine–HCl pH 8.0 for 720 s.
Kinetic studies of aBa and nsc61610
A final GST-LANCL2 surface density (RL) of 7,500 RU equivalent 
to an Rmax of 53 and 26 RU for NSC61610 and ABA, respectively, 
was obtained. Following initial binding studies, it was determined 
that binding of small molecules to the LANCL2 was occurring 
with a fast off rate. Therefore, no regeneration step was required 
following small molecule injections. Binding affinity was calcu-
lated following injection of small molecules at four different con-
centrations (12.5, 6.25, 3.13, and 1.57 µM) in triplicates. Injection 
time was 60 s and dissociation time was 300 s. Running buffer for 
binding studies was 25 mM MOPS (pH 6.5), 150 mM NaCl, 0.05% 
P-20, 5% DMSO. Data were analyzed by using the BiaEvaluation 
software v1 (GE Healthcare) with 1:1 binding model for steady 
state affinity. Raw data were exported and graphed using Prizm 
for Mac v5.0d.
statistical analysis
Data from the first mouse challenge study were analyzed as 
a series of factorial arrangement designs. To determine the 
statistical significance of the model, we performed analysis of 
variance (ANOVA) using the general linear model procedure of 
Statistical Analysis Software, and p-value <0.05 was considered 
to be significant. When the model was significant, ANOVA was 
followed by Fisher’s protected least significant difference multiple 
comparison method.
resUlTs
lancl2 aids in resolution and recovery 
from influenza infection
To assess the role of LANCL2 in the response to influenza infection, 
wild-type C57BL6/J mice and LANCL2−/− mice were infected 
with 350  pfu/mouse of influenza A H1N1/California/04/09. 
Notably, LANCL2−/− mice had a decreased rate of survival 
and prolonged presence of symptoms (Figures  1A,B). Within 
FigUre 1 | loss of lancl2 impairs resolution of influenza virus infection. Mortality (a) and disease activity (B) of WT and LANCL2−/− mice infected with 
influenza. Cell number of CD8+ IL10+ T cells (c), IL10-producing macrophages (D), CD4+ IL10+ T cells (e), neutrophils (F), type 2 innate lymphoid cells (g), and 
alveolar macrophages (h) at day 12 post-infection by flow cytometry. Concentration of IL-6 (i) and IL-10 (J) in lung homogenate at day 12 post-infection by cytokine 
bead array. Data points and error bars represent mean ± standard error of the mean (SEM). Asterisks (*) denote statistically significant (p < 0.05) differences 
between the treatment group and control (n = 12).
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the lungs of infected mice, LANCL2−/− possessed lower levels 
of IL-10 and higher levels of IL-6 at day 12 post-infection 
(Figures 1I,J). In general, LANCL2−/− displayed lower numbers 
of IL-10-producing cells within the lungs during the same period 
and specifically within CX3CR1+ macrophage and CD8+ T cell 
populations (Figures  1C–E). LANCL2−/− mice also showed 
lesser numbers of tissue repair and homeostasis cell types in 
alveolar macrophages and type 2 innate lymphoid cells at day 12 
post-infection(Figures  1G,H) while displaying greater number 
of neutrophils at day 7 post-infection (Figure 1F).
Myeloid lancl2 is required for 
Modulation of regulatory responses
Using a cre-recombinase system, myeloid (LANCL2fl/fl;LysCre+) 
and T cell-(LANCL2fl/fl;CD4Cre+) specific knockouts of 
LANCL2 were generated. Myeloid cell knockouts recapitulated the 
LANCL2−/− phenotype in terms of mortality (Figure 2A). Both 
cell specific knockouts displayed decreased levels of IL-10 within 
the lungs at day 12 post-infection similar to the LANCL2−/− 
(Figure  2B). In addition, IL-10-producing macrophages and 
CD8+ T cells were similarly decreased in CD4Cre+ and 
LysCre+ compared to LANCL2−/− (Figures  2D,E). However, 
LANCL2fl/fl;CD4Cre+ mice had significantly increased num-
bers of alveolar macrophages compared to LANCL2−/− and 
LANCL2fl/fl;LysCre+ mice (Figure 2F). The number of alveolar 
macrophages in LANCL2fl/fl;CD4Cre+ was similar to numbers 
in untreated wild-type mice. LANCL2fl/fl;CD4Cre+ mice also 
displayed lower concentrations of MCP-1 in lung homogenate 
than LANCL2−/− and LANCL2fl/fl;LysCre+ mice (Figure 2C). 
Together, these data suggest that a myeloid-specific LANCL2 
deficiency is capable of producing the same effects as the full body 
deletion of the protein.
Oral nsc61610 Treatment improves 
influenza Virus-associated lung 
immunopathology and Protects Mice 
against lethal influenza Virus infection
After observation of the importance of LANCL2 in the resolu-
tion phase of infection, we sought to identify if novel ligands of 
LANCL2 could aid in the response to influenza. First, to validate 
in  silico predictions that NSC61610 would bind to LANCL2, 
LANCL2 was expressed in E. coli. The binding of NSC61610 
FigUre 2 | Myeloid lancl2 is required for modulation of regulatory responses. Mortality (a) for LANCL2−/−, LANCL2fl/fl;CD4Cre+, and LANCL2fl/
fl;LysCre+ mice infected with influenza H1N1. Concentration of IL-10 (B) and MCP1 (c) within lung homogenate by cytokine bead array. Cell number of CX3CR1+ 
IL-10+ macrophages (D), CD8+ IL-10+ T cells (e), and alveolar macrophages (F) in lungs by flow cytometry at 12 days post-infection. Data points and error bars 
represent mean ± SEM. Asterisks (*) denote statistically significant (p < 0.05) differences between genotypes (n = 8).
5
Leber et al. Immune Modulation by LANCL2
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 178
to the purified protein was analyzed via SPR and compared to 
the natural ligand of LANCL2, ABA (Figure  3). Steady state 
equilibrium constants (KD) were determined to be 2.252 µM for 
the ABA–LANCL2 interaction, while the NSC61610–LANCL2 
was 2.305 µM. Following the validation of binding, we performed 
an assessment of the ability of NSC61610 to improve influenza 
virus-induced morbidity and/or mortality. C57BL/6 wild-type 
mice were challenged with 350 pfu/mouse of influenza A H1N1/
California/04/09. At 12 days post-infection, the mortality rate was 
60% in the control group versus 30% in the NSC61610-treated 
mice (Figure 4I). The onset of mortality differed by 1 day with 
the untreated wild-type group beginning on day 6 compared to 
day 7 in the NSC61610-treated groups. Mice were also scored on 
a daily basis through observation of physical activity and appear-
ance. NSC61610-treated mice were significantly more active and 
showed less signs of distress by this measure (Figure  4J). Our 
clinical data show that oral NSC61610 treatment improves the 
resolution of infection and accelerates the recovery from disease. 
These findings are in line with the lower mortality rates recorded 
in the group that received oral NSC61610 treatment.
To determine whether the improved clinical symptoms 
observed in NSC61610-treated mice were accompanied by 
decreased lung pathology, we evaluated microscopic lung lesions 
at 3, 7, and 12 days post-infection. Examination of lung tissue 
was based on epithelial necrosis, including presence of debris in 
large and intermediate size airways, and leukocytic infiltration 
of the mucosa and submucosa of large airways. Chronologically, 
the first pulmonary lesion detected was epithelial cell necrosis, 
with presence of necrotic cells in the airway compartment at 
day 7 (Figures  4B,E) and marginated leukocytes in adjacent 
blood vessels and in some cases with perivascular edema. At 
later stages, the predominant findings were leukocytic infiltra-
tion of the mucosa and submucosa of large and medium size 
airways (Figures 4A,B,D,E). This was followed by the presence 
FigUre 3 | Binding kinetics of lanthionine synthetase c-like 2 (lancl2) with abscisic acid (aBa) and nsc61610. Surface plasmon resonance (SPR) 
sensorgrams for the binding of varying concentrations of ABA (12.5, 6.25, 3.13, and 1.57 µM) to immobilized LANCL2 (a). Plot of maximal resonance unit versus 
concentration of ABA (B). Steady-state dissociation constant was calculated to be 2.252 µM utilizing a 1:1 binding model. SPR sensograms for the binding of 
varying concentrations of NSC61610 (12.5, 6.25, 3.13, and 1.57 µM) to immobilized LANCL2 (c). Plot of maximal resonance unit versus concentration of 
NSC61610 (D). Steady state dissociation constant was calculated to be 2.305 µM utilizing a 1:1 binding model.
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of inflammatory cells in the terminal airways (Figures  4C,F) 
on day 7 post-infection. To determine whether NSC61610 
ameliorated lung immune-pathology associated with infection, 
we scored these lesions from 0 to 4 depending on extent and 
severity. The analysis shows that NSC61610 indeed exerted 
a significant impact in the extent of lung epithelial necrosis 
(Figure  4G) and leukocytic infiltration (Figure  4H). The 
decline in epithelial necrosis scores occurred 2 days earlier in 
NSC61610-treated mice when compared to untreated mice. 
Additionally, the severity of leukocytic infiltration was signifi-
cantly lower in NSC61610-treated mice on day 7 post-challenge 
than in untreated mice. In untreated mice, the immune cell 
infiltration increased to reach a maximum score of 3 on day 7. 
In the NSC61610-treated mice the score was maintained under 
2 throughout the experiment, suggesting lower inflammatory 
cells recruited to the lungs.
In NSC61610-treated wild-type mice, oral treatment of 
NSC61610 increases expression of LANCL2 throughout the 
time course of influenza infection (Figure 4K). To confirm the 
decrease in inflammatory cell types during the peak of infection 
in NSC61610-treated mice, we measured the mRNA expression 
of inflammatory markers, IFNα, TNFα and MCP1, in the lungs 
of infected mice (Figures 4L–N). Notably, NSC61610 treatment 
reduced expression of TNFα, at day 7 post-infection, and MCP1 
at days 3 and 7 post-infection. IFNα was not significantly altered 
at any of the observed time points.
nsc61610 Promotes immunological 
Mechanisms of regulation and repair in 
the lungs
Oral administration of NSC61610 increases the number of 
IL-10-producing macrophages and CD8+ T cells (Figures 5A,B). 
The numbers of IL-10-producing CD4+ T cells and induced T 
regulatory cells were not changed by treatment (Figures 5G,H). 
Numbers of polymorphonuclear myeloid-derived suppres-
sor cells, alveolar macrophages and innate lymphoid cell type 
2 were also significantly increased at day 12 post-infection 
(Figures 5C–E). Meanwhile, neutrophils were slightly suppressed 
at the peak, day 7, of infection (Figure 5F). Using a cytokine bead 
array, the concentration in lung homogenate of cytokines was 
measured at day 12 post-infection. The concentration of IL-10 was 
significantly increased by oral NSC61610 treatment (Figure 5I). 
Trends in IL-10 production were further confirmed by qRT-PCR 
with lung tissue (Figure 5M). No significant trends were observed 
in IL-6, MCP1 or IFNγ at day 12 post-infection (Figures 5J–L). 
Expression of amphiregulin was also observed to be significantly 
increased by oral NSC61610 treatment (Figure 5N).
FigUre 4 | nsc61610 treatment decreases severity and improves recovery from influenza virus infection. Representative photomicrographs of H&E 
stained lung sections from NSC61610 (a–c) and control treated (D–F) mice following influenza infection. Summary of epithelial necrosis (g) and leukocytic 
infiltration (h) scores. Mortality (i) and disease activity (J) of WT mice infected with influenza with no treatment and NSC61610 treatment. mRNA expression of 
LANCL2 (K), IFNα (l), TNFα (M), and MCP1 (n) at days 0, 3, 7, and 12 post-infection in lung tissue during influenza infection of wild-type mice administered PBS or 
NSC61610 (20 mg/kg) by qRT-PCR. Data points and error bars represent mean ± SEM. Asterisks (*) denote statistically significant (p < 0.05) differences between 
the treatment group and control (n = 12).
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lancl2 is required for the Beneficial 
effects of nsc61610
As NSC61610 is a predicted ligand of LANCL2, we sought to 
evaluate the specificity of the ligand’s effects in LANCL2−/− 
mice. To determine if the efficacy of NSC61610 treatment is 
dependent on the presence of LANCL2, we administered PBS 
or NSC61610 to infected LANCL2−/− mice. No significant 
differences were apparent in mortality or disease activity scores 
(Figures  6A,B). Additionally, no differences were observ-
able in cellular (Figures 6C–F) or molecular (Figures 6G–J) 
measures noted to be changed in wild-type mice treated with 
NSC61610.
effects of nsc61610 are Mediated by 
il-10
Mice were infected with influenza virus as previously. After infec-
tion, mice were administered an IL-10 neutralizing antibody or 
isotype control. IL-10-neutralized mice treated with NSC61610 
exhibited no differences from untreated IL-10-neutralized 
mice in clinical measures of disease activity index and mor-
tality (Figures  7A,B). The isotype control antibody did not 
dampen the efficacy of NSC61610 against influenza. The IL-10 
neutralization inhibited the increases in alveolar macrophages, 
CD103+ dendritic cells, and ILC2 experienced with NSC61610 
treatment (Figures  7C,D,G). The neutralization of IL-10 also 
significantly increased the number of IFNγ-producing CD4+  
T cells (Figure 7F). However, the neutralization of IL-10 did not 
reduce the NSC61610-mediated increase in myeloid-derived 
suppressor cells (Figure 7E).
nsc61610 or combined Therapy with 
nsc61610 and Tamiflu Outperforms 
Tamiflu alone
To determine whether the treatment efficacy of NSC61610 could 
be further increased by combination with an antiviral agent, we 
administered NSC61610 in combination with oseltamivir phos-
phate, an active ingredient of Tamiflu. NSC61610 and combina-
tion treatment improved the overall mortality and disease activity 
compared with treatment with oseltamivir alone (Figures 8A,B). 
Notably, treatment only with Tamiflu did not promote cellular 
regulatory responses within the lungs while the combination 
therapy retained the regulatory benefits of NSC61610 treatment 
(Figures  8C–E). After the observation that treatment with 
NSC61610 induces regulatory and anti-inflammatory effects, we 
sought to determine if these effects impacted the viral burden 
within the lungs. The amount of virus was titrated by plaque 
assay of MDCK cells. Treatment with NSC61610 did not alter 
the amount of virus detected. Both Tamiflu and combination 
therapies significantly reduced the viral titer (Figure 8F).
DiscUssiOn
The LANCL2 pathway has emerged as a therapeutic target for 
inflammatory, chronic, and immune-mediated diseases (15). 
FigUre 5 | nsc61610 Promotes regulatory responses during resolution Phase of infection. Cell number of IL10-producing macrophages (a), CD8+ 
IL10+ T cells (B), polymorphonuclear myeloid-derived suppressor cells (c), alveolar macrophages (D), type 2 innate lymphoid cells (e), neutrophils (F), CD4+ IL10+ 
T cells (g), and induced T regulatory cells (h) through day 12 post-infection by flow cytometry. Concentration of IL-10 (i), IL-6 (J), MCP-1 (K), and IFNγ (l) in lung 
homogenate at day 12 post-infection by cytokine bead array. mRNA expression of IL10 (M) and amphiregulin (n) in lung at day 12 post-infection by qRT-PCR. Data 
points and error bars represent mean ± standard error of the mean (SEM). Asterisks (*) denote statistically significant (p < 0.05) differences between the treatment 
group and control (n = 12).
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By using pharmacologic activation of LANCL2 and loss-of-
function approaches in knockout mice, we validate the LANCL2 
pathway as a putative target for the treatment of influenza 
infection. ABA binds to LANCL2 (13) and causes elevation 
of intracellular cAMP and activation of PKA in macrophages 
(11). In addition, ABA suppressed LPS-induced inflammation 
in mice (11), experimental colitis (25, 26), and accelerated 
recovery in influenza virus-driven lung immunopathology (14). 
Previous work on ABA illustrates the similarities in host defense 
mechanisms between plants and animals and the importance 
of understanding a common evolutionary heritage. Based on 
the demonstrated efficacy of ABA as an immune modulatory 
compound and the discovery of the anti-inflammatory efficacy 
of the LANCL2 pathway, we screened chemical databases 
to identify new compounds that bind to LANCL2 and found 
that NSC61610 had the highest predicted binding affinity (19). 
Previous studies demonstrated the efficacy of NSC61610 as an 
anti-inflammatory compound in mouse models of colitis (19). 
Moreover, BT-11, a new LANCL2 ligands being developed for 
treating IBD, has an outstanding safety profile based on single 
and 14-day repeated-dose toxicology studies in rats, and it 
outperforms current IBD treatments in mice with dextran 
sodium sulfate colitis (20–22). Recently, the binding of LANCL2 
to ligand has been shown to affect the cellular localization of 
FigUre 6 | loss of lancl2 impairs recovery and diminishes clinical effects of nsc61610 treatment. Mortality (a) and disease activity (B) of LANCL2−/− 
mice infected with influenza with no treatment and NSC61610 treatment. Cell number of CD8+ IL10+ T cells (c), IL10-producing macrophages (D), alveolar 
macrophages (e), and neutrophils (F) through day 12 post-infection by flow cytometry. Concentration of IL-10 (g) and IL-6 (h) in lung homogenate at day 12 
post-infection by cytokine bead array. mRNA expression of amphiregulin (i) and IL10 (J) in lung at day 12 post-infection by qRT-PCR. Data points and error bars 
represent mean ± SEM. Asterisks (*) denote statistically significant (p < 0.05) differences between the treatment group and control (n = 12).
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LANCL2 resulting in multiple methods of promoting down-
stream effects (27).
Our in  vivo results demonstrate for the first time that oral 
treatment with NSC61610 and activation of the LANCL2 pathway 
ameliorates pulmonary immunopathology during influenza A 
virus infection by suppressing inflammation and enhancing IL-10-
mediated immunoregulatory responses in the lungs. Specifically, 
oral treatment with NSC61610 lowered infiltration of the airway 
mucosa and submucosa and decreased epithelial necrosis in lungs 
of infected mice. NSC61610 exerted its anti-inflammatory effect 
by suppressing TNF-α and MCP-1 expression during early and 
peak phases. TNF-α is a pro-inflammatory cytokine implicated 
in priming epithelial cells for induced cytokine and chemokine 
production during influenza A virus infection, while MCP1 
contributes to the recruitment of immune cells (28). Anti-TNF-α 
humanized antibodies, such as Remicade (Centocor, Malvern, 
PA, USA) and Humira (Abbott Laboratories, Abbott Park, IL, 
USA) are biologics that have been approved by the Food and 
Drug Administration as therapeutics against immune-mediated 
diseases, such as IBD (29). The discovery of a small molecule 
with an oral route of administration that decreases these two 
inflammatory mediators expression through the selective and 
novel LANCL2 pathway holds similar promise in the treatment of 
autoimmune disorders and pathogen-initiated immunopatholo-
gies. At the cellular level, oral NSC61610 treatment significantly 
decreased the numbers of infiltrating neutrophils in the lungs of 
influenza virus-infected mice. Pulmonary neutrophil infiltra-
tion is a prominent feature of the early inflammatory response 
to influenza virus infection of humans, ferrets, and mice (30). 
Neutrophils constitute a large proportion of the inflammatory 
leukocytes infiltrating the lung during influenza virus infection. 
Although their role in influenza virus clearance is not yet well 
defined, it has been suggested that excessive neutrophils and 
neutrophil extracellular traps contribute to acute lung injury of 
influenza pneumonitis (31).
While differences in inflammatory markers exist through-
out the course of infection, the efficacy of oral treatment with 
NSC61610 is most apparent during the recovery phase, in which 
the increased activation of immunoregulatory pathways is most 
prevalent. Similar improvements in the recovery phase were 
reported by oral treatment of influenza virus-infected mice with 
ABA, the first LANCL2 ligand discovered (14). Notably, the 
administration of ABA has been shown to activate PPARγ in a 
LANCL2-dependent manner suggesting that LANCL2 agonists 
FigUre 7 | il10 neutralization abrogates efficacy of nsc61610. Disease activity (a), and mortality (B) of wild-type mice following IL10 neutralization during 
influenza infection. Cell number of alveolar macrophages (c), CD103+ dendritic cells (D), polymorphonuclear myeloid-derived suppressor cells (e), CD4+ IFNγ+  
T cells (F), and type 2 innate lymphoid cells (g) within lungs at day 12 post-infection by flow cytometry. Data points and error bars represent mean ± SEM. Asterisks 
(*) denote statistically significant (p < 0.05) differences between the NSC61610 treatment group and control (n = 8). Number signs (#) denote statistically significant 
(p < 0.05) differences between neutralization treatment group and control (n = 8).
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may contribute to the activation of this regulatory pathway (11). 
We provide molecular evidence in vivo that NSC61610 functions 
in a LANCL2-dependent manner during the recovery phase of 
infection, since the beneficial effects of NSC61610 treatment 
observed in wild-type mice are abrogated in LANCL2 knockout 
mice. Indeed, the largest differences in clinical disease measures, 
such as weight loss and mortality occur after the peak of infection 
as the NSC61610-treated wild-type group experienced an earlier 
and more pronounced weight gain and decrease in mortality 
during this phase. Oral treatment with NSC61610 triggers a 
shift toward a regulatory tissue environment, evidenced by the 
increased LANCL2-dependent expression of IL-10 in the lungs.
As a crucial regulatory cytokine, IL-10 has previously been 
shown to suppress pulmonary inflammation and tissue damage 
(32, 33). The cytokine exerts its regulatory control through a 
signaling cascade resulting in the downregulation of inflam-
matory cytokines, such as MCP-1 or IFN-γ, the rampant 
production of which contribute to the damaging cytokine storm 
(34). At the cellular level, oral treatment with NSC61610 induced 
increased levels of IL-10-producing CD8+ T cells and CD11b+ 
F4/80hiCX3CR1+ macrophages in the lungs. CX3CR1+ mac-
rophages are a myeloid cell type prominent in the promotion 
of a homeostatic tissue environment, predominately tied to the 
control of intestinal immune responses to bacteria (35). Some 
inflammatory subsets of macrophages have been identified as 
susceptible to influenza infection and are crucial mediators of 
the well-categorized cytokine storm associated with the influ-
enza virus (36). The ability of LANCL2 activation to promote a 
regulatory, IL-10-producing, macrophage population suggests 
efficacy of this pathway to control the damaging effects of the 
influenza virus in the lungs throughout the course of infection. 
CD8+ T cell responses mediate resistance against intracellular 
infections through effector mechanisms with the potential to 
defend against infection (37). For example, CD8+ T cells could 
FigUre 8 | combination of nsc61610 and Tamiflu promotes regulatory responses and suppresses viral replication. Mortality (a) and disease activity (B) 
of mice treated with PBS, Tamiflu (10 mg/kg/day), Tamiflu and NSC61610 (5 and 10 mg/kg/day respectively), or NSC61610 alone (20 mg/kg/day). Cell number of 
CD8+ IL10+ T cells (c), IL10-producing macrophages (D), and alveolar macrophages (e) at day 12 post-infection by flow cytometry. Viral titer (F) within the lungs 
on day 3 post-infection by MDCK cell plaque assay. Data points and error bars represent mean ± SEM. Asterisks (*) denote statistically significant (p < 0.05) 
differences between the combination treatment group and control (n = 12). Number signs (#) denote statistically significant (p < 0.05) differences between Tamiflu 
treated and control groups (n = 12). Ampersands (&) denote statistically significant (p < 0.05) differences between combination and single treatment groups (n = 12).
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eliminate influenza-virus-infected targets via the perforin/gran-
zyme B, Fas/FasL, or TRAIL pathways (38). Meanwhile, CD8+ 
T cells have previously been identified as the main producer of 
IL-10 in the lungs during influenza infection (33). While recent 
evidence suggests that the production of IL-10 from T cells may 
be crucial in switching from innate to adaptive immunity during 
infection and lesser production may be connected to enhanced 
morbidity in young populations (39). Treatment with NSC61610 
or similar LANCL2 ligands may help to boost this switch and 
prevent age-associated morbidities. The production of IL-10 
from this subset, which can also be driven to secrete the effector 
cytokine IFNγ, is initiated in part through the presence of IL-4 
within the environment (40).
IL-4 is a prototypical Th2-associated cytokine that is also 
produced by dendritic cells and innate lymphoid cells (41, 42). In 
particular, the loss of the type 2 innate lymphoid cell population 
during influenza infection creates a loss of epithelial integrity 
and decreased lung function (43). The increased expression of 
multiple ILC2-related genes upon treatment with NSC61610 
indicates the involvement of LANCL2 in the generation and 
maintenance of this cellular phenotype. The dual roles of IL-4, 
as a chemoattractant stimulant of macrophages and eosinophils 
and an inhibitor of pro-inflammatory cytokines, such as TNF-α 
and MIP-1, may suggest that its acute elevation can allow for 
ample recruitment of antiviral cells while decreasing the likeli-
hood of an excessive cytokine storm (44, 45). In addition to the 
IL-10-related effects, a key mediator of the regulatory response 
is the growth factor, amphiregulin. A direct product of immune 
cells, amphiregulin has both traditional growth factor effects, 
in the maintenance and stimulation of epithelial cell growth, 
as well as additional regulatory mechanisms, via the promo-
tion of regulatory T cells (46, 47). The increased expression of 
amphiregulin with LANCL2 activation may be a key component 
in the reduction of epithelial necrosis and lung damage during 
infection.
PMN-MDSCs, alternatively referred to as granulocytic MDSC, 
have been shown to resolve inflammation through the attenuation 
of T cell expansion and inflammatory cytokine production via 
direct cell-to-cell contact, producing a highly local and specific 
suppressive effect (48). The presence of PMN-MDSCs during the 
neutralization of IL-10 suggests that this cellular phenotype is 
capable of being established by NSC61610 in the absence of IL-10. 
Without the amplification of immunoregulatory effects by IL-10, 
the expanded MDSC population is unable to reduce disease 
severity or aid in the resolution of infection. This suggests that, 
while MDSCs may assist in the resolution of infection, IL-10-
producing cells are the critical effectors of NSC61610 treatment 
and LANCL2 activation.
The spectrum of regulatory effects promoted by LANCL2 
is dependent on signaling within myeloid cells and T cells. The 
promotion of IL-10-producing macrophages and CD8+ T cells 
is lost both in T cell and myeloid-specific knockouts of LANCL2 
suggesting that interplay between the cell types is necessary to 
induce these effects. In contrast, the suppression of inflammatory 
cytokine production and increased number of alveolar mac-
rophages remained intact within T cell knockouts of LANCL2. 
Alveolar macrophages are responsible for initiating many of the 
virus clearing responses in addition to the promotion of tissue 
remodeling and prevention of secondary infections (49–51). 
Therefore, the myeloid LANCL2- and IL10-dependent effects of 
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NSC61610 administration are greatly beneficial to the alveolar 
macrophage-mediated pathways of host defense.
A concern with immunoregulatory treatment of infectious 
disease is impaired clearance or increased burden of the infec-
tious agent. However, no difference in viral load was observed 
at day 3 post-infection with NSC61610 treatment. When also 
treated with Tamiflu, the viral load at day 3 post-infection was 
decreased. Despite a lower viral load, mice treated only with 
Tamiflu did not exhibit the regulatory responses exhibited by 
NSC61610-treated mice, suggesting the regulatory benefits of 
NSC61610 are independent of changes in viral load. Indeed, 
the therapeutic efficacy of NSC61610 has been shown in non-
infectious disease models (15). Additionally, treatment with 
NSC61610 significantly increased survival rates compared to 
Tamiflu-treated mice. While Tamiflu is directly effective against 
specific strains of influenza A, there is risk for adaptive strains 
to evade its inhibitory effects. Also, the treatment schedule of 
Tamiflu is very dependent on fast identification and treatment 
initiation with as little as a 24 h delay nullifying the beneficial 
effects. In contrast, NSC61610 treatment was initiated at 24 post-
infection in all studies and retained effects.
Though not analyzed presently, the immunoregulatory ben-
efits of LANCL2 activation during resolution of influenza virus 
infection may help to bolster lasting memory responses to the 
viral antigen. Across viral, bacterial, and parasitic infections, the 
increased production of IL-10 has been shown to aid in the matu-
ration of memory CD4+ and CD8+ T cells (52–54). As a result, 
treatment with NSC61610, or similar LANCL2 ligand, could also 
aid in the efficient generation of highly specific response upon 
secondary exposure. However, conflicting reports exist on the 
effect of IL10+ CD8+ T cells, MDSCs, and immunoregulatory 
therapies on the ability to expand immediate memory responses 
(55, 56). Therefore, further research should be conducted into the 
effect of NSC61610 and LANCL2 activation on the generation 
and maturation of memory responses.
In summary, our data demonstrates for the first time that oral 
NSC61610 treatment ameliorates the morbidity and mortality 
associated with pandemic H1N1pdm influenza virus infection 
by suppressing the trafficking of inflammatory tissue-damaging 
cells (i.e., monocytes and neutrophils) and increasing IL-10-
producing CD8+ T cells and regulatory macrophages in the lungs 
in a LANCL2-dependent manner, thereby validating the role of 
the LANCL2 pathway as a novel host-targeted therapeutic against 
influenza that modulates the balance of effector and regulatory 
host responses in the lungs and systemically. NSC61610 improves 
clinical measures of disease compared to a current standard of 
care, oseltamivir (Tamiflu). Given the risk of developing resist-
ance to Tamiflu and other agents targeting directly the virus, 
future studies should explore utilizing LANCL2-based host-
targeted therapeutics in combination with lower doses of licensed 
antiviral drugs.
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